MedTrace Logo

Safety and Tolerability of PRO-143 Ophthalmic Solution in Healthy Volunteers.

NCT03698045 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2018-10-10

No results posted yet for this study

Summary

Study to evaluate the safety and tolerability of PRO-143 solution ophthalmic in healthy volunteers.

Conditions

  • Conjunctivitis, Bacterial

Interventions

DRUG

PRO-143 Ophthalmic Solution

PRO-143 Ophthalmic Solution applied four times per day (C/6 hours) during 10 days.

Sponsors & Collaborators

  • Laboratorios Sophia S.A de C.V.

    lead INDUSTRY

Principal Investigators

  • José F Alaniz-De La O, MD · Independent Clinical Research Center

  • Laura R Saucedo-Rodíguez, MD · Independent Clinical Research Center

  • Leopoldo M Baiza-Durán, MD · Clinical Research Department. Laboratorios Sophia SA de CV

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2014-02-28
Completion
2014-03-31

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03698045 on ClinicalTrials.gov